|
|
|
Propulsid - Class Action Information
|
On March 23, 2000, the US Food and Drug Administration (FDA) announced that Janssen Pharmaceutica
(a wholly-owned subsidiary of Johnson & Johnson) would cease marketing of cisapride (Propulsid) in the United
States as of July 14, 2000. In its announcement, the FDA stated that as of December 31, 1999, use of cisapride
has been associated with 341 reports of heart rhythm abnormalities including 80 reports of deaths. Propulsid had
been used as a treatment for severe nighttime heartburn experienced by adult patients with gastroesophageal reflux
disease (GERD). Propulsid had been approved by the FDA in tablet form in 1993, and in suspension form in 1995.
A variety of lawsuits have been filed against Janssen Pharmaceutica and Johnson & Johnson over the effects of Propulsid.
Return to Main
|
|
